anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The carer identifies the patient and scans a barcode attached to the medical item such as a drug container. A computer system verifies the credential of the patient and the drug, such as in the case of the drug the dosage and the expiry date. The carer uses a battery operated terminal which may communicate wirelessly with an integrated records system. Also claimed is apparatus for storage of medical items comprising a frame with castors, an electronically operative assembly, a handle for steering, locking doors and a plurality of storage compartments. The apparatus may also be a self-propelled medication trolley comprising a transaxle driving unit which is mounted to the rear of the medication trolley base. The base unit can contain two rechargeable batteries which provide power to an electric motor, integrated computer system and light. The trolley incorporates secure and flexible compartments for storing and transporting medication in dosage card racks and/or manufacturers' original packaging as desired.
Days 1 through 7, each subject received a placebo run-in. Days 8 through 21, 2 sprays (2 × 50 μg) of Mometasone Furoate Monohydrate Nasal Spray per nostril once daily for 14 days. Total Daily Dose = 4 × 50 μg = 200 μg.
The invention discloses a drug-loaded nanoparticle. The active ingredient of the drug-loaded nanoparticle is vancomycin hydrochloride, the carrier material is formed by compounding carboxylated chitosan and chitosan quaternary ammonium salt through ionic crosslinking, and the mass ratio of the carboxylated chitosan to the chitosan quaternary ammonium salt is 10: 1-5. The drug-loaded nanoparticles can obviously improve the drug loading rate of vancomycin, can achieve biodegradability, and can be used for treating osteomyelitis. The invention also provides a preparation method and application of the drug-loaded nanoparticles. Based on the drug-loaded nanoparticles, the invention also provides a preparation method and application of the hydrogel. The temperature sensitive characteristic of the hydrogel is utilized, so that the hydrogel is beneficial to the administration of the hydrogel to the focus part, and can slowly release the drug at the focus part to improve the focus part.
Quinoline-based fibroblast activation protein (FAP) inhibitors (FAPIs; e.g., FAPI-04 and FAPI-46), which have shown promising results in the diagnosis of cancer and various other diseases in recent years, have become the focus of much productive research. Despite this, one major issue is that these FAPI molecules have a relatively short tumor retention time, which may limit their use in targeted radionuclide therapy applications. As a result, 68Ga-DOTA-F2, a novel dimeric FAPI molecule, was developed to increase tracer uptake and retention in tumors for potential therapeutic or theranostic applications. In preclinical study, 68Ga-DOTA-F2 has shown better tumor uptake and longer tumor retention time than 68Ga-FAPI in mouse tumor models. Our study will assess image quality and evaluate the diagnostic performance of 68Ga-DOTA-F2. Patients with histologically confirmed malignant tumors will be prospectively recruited in this study.
Acute liver injury (ALI) refers to the damage to the liver cells of patients due to drugs, food, and diseases. In this work, we used a network pharmacology approach to analyze the relevant targets and pathways of the active ingredients in Citri Reticulatae Pericarpium (CRP) for the treatment of ALI and conducted systematic validation through in vivo and in vitro experiments. The network pharmacologic results predicted that naringenin (NIN) was the main active component of CRP in the treatment of ALI. GO functional annotation and KEGG pathway enrichment showed that its mechanism may be related to the regulation of PPARA signaling pathway, PPARG signaling pathway, AKT1 signaling pathway, MAPK3 signaling pathway and other signaling pathways. The results of in vivo experiments showed that (NIN) could reduce the liver lesions, liver adipose lesions, hepatocyte injury and apoptosis in mice with APAP-induced ALI, and reduce the oxidative stress damage of mouse liver cells and the inflammation-related factors to regulate ALI. In vitro experiments showed that NIN could inhibit the proliferation, oxidative stress and inflammation of APAP-induced LO2 cells, promote APAP-induced apoptosis of LO2 cells, and regulate the expression of apoptotic genes in acute liver injury. Further studies showed that NIN inhibited APAP-induced ALI mainly by regulating the PPARA-dependent signaling pathway. In conclusion, this study provides a preliminary theoretical basis for the screening of active compounds in CRP for the prevention and treatment of ALI.
A machine is provided which includes a pick-up station adapted to receive flat confection discs from a baking machine, and feed them in succession to a rotary wheel at a forming station to lap fold the discs into taco shape. A fixed elongated support rail having a curved upper surface extends generally the length of the conveyor and receives the folded shells thereover so that the shells hang therefrom. An endless belt is coextensive with the support rail and biasingly holds the formed shells to the rail and frictionally drives the shell freely slidingly therealong. A pair of shell leg receiving channels are disposed beneath the support rail, with the channels formed by inner and outer generally parallel walls coextensive with the rail. The inner walls are defined by a support device beneath the rail while the outer walls are formed by plates which are transversely adjustable to thereby control the channel width and shell leg angle. In the embodiment disclosed, the support rail and support device are tubular and fluid flows therethrough to cool and harden the formed shells. The traveling folded shells are subjected to an oil spray which tends to make the shells remain crisp and generally impervious to moisture from a subsequently applied filling. Furthermore, the drive belt is cooled adjacent the shell discharge to counteract belt expansion covered by engagement with the hot baked shells.
Coronary Artery Disease (CAD) is the leading cause of death worldwide. CAD refers to the pathological process of atherosclerosis that affects the coronary arteries, often leading to obstruction by an atheromatous plaque. Oxidative stress is one of the most potent inducers of vascular inflammation in atherogenesis. Reactive oxygen species (ROS) regulate through nuclear factor kB (NF-kB), transcription factors and genes related to inflammation, thus, activation of NF-kB by ROS in the atherosclerosis patient is associated with vascular dysfunction and thus with inflammation and atherosclerosis. Recently, researchers have discovered a transcription factor identified as nuclear factor-erythroid 2-related factor 2 (Nrf2) transcription factor, which is responsible for the expression of antioxidant response element genes that can inhibit this pathway, thus providing cellular protection. Thus, several nutritional strategies have been studied, including the use of curcumin, a chemical compound of the class of curcumin produced by turmeric root (Curcuma longa). Turmeric is capable of promoting the activation of nuclear factor-erythroid 2-related factor 2 (Nrf2) transcription factor and inflammasome (NLPR3). These factors, in turn, are involved with the activity of nuclear factor kappa-B (NF-kB), a transcription factor that increases the synthesis of inflammatory cytokines. Thus, the present study aims to evaluate the effects of turmeric supplementation on cardiovascular risk markers, inflammation, oxidative stress and evaluation of functional capacity. Perspectives: This study aims to improve the inflammatory and oxidative stress status of patients with CAD with the use of turmeric, and thus try to reduce the risk factors related to the onset and progression of coronary artery disease.
After the administration of local anesthesia, the dimension of the needed graft will be marked by a #15c blade and then diode laser de-epithelization will take place. The de-epithelized area will be then harvested using a # 15c blade. The donor site will be covered by cyanoacrylate tissue adhesive dressing .
BACKGROUND: The prevalence of, and risk factors for, genital Human Papillomavirus (HPV) infections within the young adult population are well-established; the same is not known for oral HPV. This observational study aimed to determine oral HPV prevalence and abundance within a UK young adult population, and examine if sexual practices and established risk factors of oropharyngeal squamous cell carcinomas (OPSCCs) (such as smoking and alcohol consumption) influenced HPV prevalence.
METHODS: Convenience sampling was used to recruit a small sample of 452 UK-based young adults studying at a higher education (HE) institution to the study; the study was not powered. A highly sensitive real-time PCR HPV screening method was developed for the detection of multiple HPV subtypes from oral swabs. HPV-positive samples were subsequently screened by qPCR for viral subtypes HPV-6, HPV-11, HPV-16, HPV-18. Results were analysed by univariate and multivariate methods and stratified for gender, with lifestyle behaviour data collected via questionnaire. Socio-economic status was not captured within the questionnaire.
RESULTS: We found a high oral HPV prevalence of 22.79%, with a dominance of high-risk viral type HPV-16 (prevalence 19.12%; abundance average 1.08 × 105 copies/million cells) detected within healthy young adults. Frequent smoking (p = .05), masturbation (p = .029), and engagement in multiple sexual activities (p = .057), were found to be associated with oral HPV prevalence, and HPV-16 prevalence, whilst behaviours traditionally associated with genital HPV were not.
CONCLUSIONS: Our results strengthen the link between sexual practices and oral HPV transmission. We suggest that young adults should be considered high-risk for the contraction of oral HPV, although acknowledge that this sample of HE students may not be representative of the wider population. We show that high-risk HPV-16 is prevalent in the healthy population, as well as dominating within OPSCC; this study is one of the first to determine the dominance of oral HPV-16 prevalence and abundance within this population, presenting a clear need for greater awareness of oral HPV infections, and the risk factors for HPV-positive OPSCC within young adults.
Risk Summary

There are no data on the presence of rolapitant in human milk, the effects of rolapitant in the breastfed infant, or the effects of rolapitant on milk production. Rolapitant administered orally to lactating female rats was present in milk (see Data). The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for VARUBI and any potential adverse effects on the breastfed infant from VARUBI or from the underlying maternal condition or the use of concomitant chemotherapy. 

Data

Radioactivity from labeled [14C] rolapitant was transferred into milk of lactating rats following a single oral dose of 22.5 mg/kg, and the maximum radioactivity in milk was observed at 12 hours post-dose. The mean milk/plasma radioactivity concentration ratios in dams at 1 to 48 hours post-dose ranged from 1.24 to 3.25. Based on average daily consumption of milk (2 mL/day) and the maximum milk radioactivity determined, pup exposure is expected to be 0.3% of the orally administered dose.
Butorphanol produces respiratory depression by direct action on brain stem respiratory centers. The respiratory depression involves a reduction in the responsiveness of the brain stem respiratory centers to both increases in carbon dioxide tension and electrical stimulation.

In human studies involving individuals without significant respiratory dysfunction, 2 mg of butorphanol IV and 10 mg of morphine sulfate IV depressed respiration to a comparable degree. At higher doses, the magnitude of respiratory depression with butorphanol is not appreciably increased; however, the duration of respiratory depression is longer. Respiratory depression noted after administration of butorphanol to humans by any route is reversed by treatment with naloxone, a specific opioid antagonist (see OVERDOSAGE).

Butorphanol, like other mixed agonist-antagonists with a high affinity for the kappa receptor, may produce unpleasant psychotomimetic effects in some individuals.

Nausea and/or vomiting may be produced by doses of 1 mg or more administered by any route.

In human studies of butorphanol (see CLINICAL PHARMACOLOGY; Clinical Trials), sedation is commonly noted at doses of 0.5 mg or more. Narcosis is produced by 10 to 12 mg doses of butorphanol administered over 10 to 15 minutes intravenously.

Butorphanol causes miosis, even in total darkness. Pinpoint pupils are a sign of opioid overdose but are not pathognomonic (e.g., pontine lesions of hemorrhagic or ischemic origins may produce similar findings). Marked mydriasis rather than miosis may be seen due to hypoxia in overdose situations.
A nutritional beverage or drink is provided having resveratrol mixed with water, suspended in a liquid suspension system. One or more of quercetin, catechins, antioxidants, energy agents, sweeteners, preservatives, pH balancing ingredients, and coloring agents may also be included. A process is provided for preparing a dietary supplement drink in a liquid suspension, comprising mixing water in a suspension system with resveratrol. The process may also include adding one or more of quercetin, catechins, antioxidants, energy agents, sweeteners, preservatives, acidulants, and coloring agents. The nutritional beverage or drink may also be modified by using pure water that has nanosized water clusters therein, as well as mixing into the liquid suspension nanoparticles of resveratrol and/or one or more of the above ingredients to enhance the bioavailability of the ingredients. The compositions may be used to treat diseases and bodily malfunctions.
This invention provides a novel probe, which contains a prostate peptide substrate. The probe can be used as a prostate diagnostic agent for optical imaging. An 11 amino acid peptide substrate is synthesized for specific prostate-specific antigen (PSA). This protected graft copolymer (PGC) consists of a poly-L-lysine (PL) backbone and methoxypoly(ethylene glycol) (MPEG). Two terminals of peptide substrate are bound to poly-L-lysine and Cy5.5 fluorochrome. This probe will be used as a NIR (near-infrared fluorescence) probe for optical imaging.
The present application provides novel quinazolines and azaquinazolines and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful in for co-regulating RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways by administering a therapeutically effective amount of one or more of the compounds of formula (I), wherein X, Y, T and R 4 , and R 6  to R 8'  are defined herein, to a patient. By doing so, these compounds are effective in treating conditions associated with the dysregulation of the RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways. A variety of conditions can be treated using these compounds and include diseases which are characterized by abnormal cellular proliferation. In one embodiment/ the disease is cancer.
BACKGROUND: Pain is associated with reports of restricted physical activity (PA), yet the association between musculoskeletal pain characteristics and objectively measured PA quantities and patterns in late life is not well understood.
METHODS: A total of 553 adults (mean age 75.8 ± 8.4 years, 54.4% women) in the Baltimore Longitudinal Study of Aging (BLSA) completed a health interview and subsequent 7-day wrist-worn ActiGraph assessment in the free-living environment between 2015 and 2020. Pain characteristics, including pain presence in 6x sites (ie, shoulders, hands/wrists, low back, hip, knees, and feet), pain laterality in each site, and pain distribution were assessed. PA metrics were summarized into total daily activity counts (TAC), activity fragmentation, active minutes/day, and diurnal patterns of activity. Linear regression models and mixed-effects models examined the association between pain characteristics and PA outcomes, adjusted for demographics and comorbidities.
RESULTS: Unilateral knee pain was associated with 184 070 fewer TAC (p = .039) and 36.2 fewer active minutes/day (p = .032) compared to those without knee pain. Older adults with shoulder pain or hand/wrist pain had more active minutes compared to those without pain (p < .05 for all). For diurnal patterns of activity, participants with knee pain had fewer activity counts during the afternoon (12:00 pm to 5:59 pm). Analyses stratified by sex showed that these associations were only significant among women.
CONCLUSIONS: Our study highlights the importance of assessing pain laterality in addition to pain presence and suggests that pain interferes with multiple aspects of daily activity. Longitudinal studies are needed to assess the temporality of these findings.
Tablets, granules and other bodies of compressed powdery material for pharmaceutical use and food products such as cubes of meat extract include from 0.5 to 15 per cent of their total weight of a cation exchange resin not containing silver ions.  Preferably the resin is of particle size not less than about 30 B.S. mesh. Specified resins include carboxylic resins, sulphonated polyamine, phenolic, polystyrene and amine resins.  They may be used in the acid or salt (sodium, potassium or ammonium) form as desired. Conventional additives such as starch, lubricants and wetting agents may also be incorporated in the tablets.  In an example, a mixture of phenobarbitone, lactose, starch and gelatin is granulated and formed into tablets using magnesium stearate as lubricant and a carboxylic cation exchange resin such as that sold under the Registered Trade Mark "Amberlite" XE-88.
The invention provides a recombinant Newcastle disease virus for expressing chicken infectious bronchitis virus S protein and a preparation method and application thereof, belonging to the technical field of biological medicine. In order to improve the immunity rate of chicken infectious diseases. The invention provides a recombinant Newcastle disease virus for expressing chicken infectious bronchitis virus S protein, which is a vaccine strain simultaneously expressing gene VII type Newcastle disease virus F protein, HN protein and infectious bronchitis virus GI-19 genotype strain spike protein, and is named as rLa-FHN-OPSFTM, wherein the accession number is as follows: CGMCC NO. 20131. The recombinant virus which has high protein expression level and good immunogenicity and can provide solid protection for the epidemic virulent strains of the Newcastle disease virus and the infectious bronchitis virus in China is obtained by screening. The recombinant virus obtained by the invention can be used as a candidate strain of a bivalent vaccine for preventing Newcastle disease and infectious bronchitis, and has important practical application value.
PURPOSE: Cancer-related fatigue is a subjective, distressing, and common sequela of cancer which is often disregarded and underdiagnosed. Fatigue is assessed by self-report requiring communication between patient and physician. In this study, we investigated the patients' perspective on the patient-physician communication about fatigue.
METHODS: On average five months after diagnosis 1179 cancer patients, recruited in Germany, completed a survey as part of the LIFT project. The survey included questions on sociodemographic data, fatigue, depression, fatigue management, patient-physician communication, and communication barriers. Data were analyzed descriptively and using logistic regression analyses.
RESULTS: Half of the participants reported that their physician had never asked them whether they felt exhausted. Patients undergoing chemo-, radio-, or immunotherapy were more likely to be asked about fatigue, while older age and major depression decreased the likelihood. Sixty-four percent of the patients felt impeded by communication barriers. Common barriers were not knowing who to turn to for fatigue (39%), time constraints (31%), and the fear of being perceived as weak (22%). Almost half of the participants indicated that their physicians were not appreciative and did not deal adequately with fatigue-related questions.
CONCLUSION: This study revealed gaps in the patient-physician communication regarding cancer-related fatigue. Contrary to guideline recommendations a minority of physicians addressed fatigue. On the other hand, cancer patients felt reluctant to bring up this topic due to structural barriers and fears. Physicians should routinely address fatigue and adopt a communication style which encourages patients to likewise state their symptoms and raise their questions.
TRIAL REGISTRATION: Clinicaltrials.gov, identifier: NCT04921644. Registered in June 2021.
Patients were to receive chemotherapy every 30 days as neoadjuvant treatment. After receiving 2 cycles of treatment, patients will be evaluated for tumor necrosis rate.
The invention discloses a preparation method of a medicament solid preparation. The method comprises the following steps of: dissolving active ingredients of a water-insoluble and/or water-poorly-soluble acid medicament into an alkaline solution containing a basifier to obtain a medicament-containing alkaline liquid; and uniformly mixing auxiliary materials with the medicament-containing alkaline liquid, and performing wet process pelletizing. The invention further discloses a medicament solid preparation prepared with the method. Due to the adoption of the preparation method disclosed by the invention, the defects of severe pollution, large loss and severe potential safety hazard caused by mechanical smashing treatment are overcome, and the effects of reducing the particle sizes of the active ingredients of the water-insoluble and/or water-poorly-soluble acid medicament in a pelletizing process is achieved. The method is easy and convenient to operate, is practicable, has high safety coefficient, and is easily applied to industrial production. The solid preparation prepared with the method has excellent dissolving characteristic, stability and content uniformity.
A composition of matter for enhancing delivery of bioactive compounds, particularly cannabinoids into the human and animal organisms. The invention enhanced oral, transmucosal and transdermal delivery of a bioactive compound including cannabinoids through the use of an excipient having a desired ratio of fatty acids, and the inclusion of terpenes and terpenoids. The invention particularly includes a lipophilic phytocannabinoid such as THC or CBD, an excipient fatty acid profile including palmitoleic acid and fatty acids selected from the group consisting of oleic acid and palmitic acid, together with terpenes and terpenoids, and combinations thereof in optimal ratios. Essential oils steam-distilled from plants and other organisms are preferred sources for the terpenes and terpenoids. Macadamia nut oil is a preferred excipient having the desired lipid profile. Macadamia nut oil is a non-toxic plant nut oil, offers oxidation resistance to the fatty acids, cannabinoids and terpenes to improve product shelf life, and has a sufficiently low melting temperature to remain fluid while refrigerated to further enhance product shelf life without changing the product phase from a fluid to a solid.